Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
bioRxiv (2021) - Comments
doi: 10.1101/2021.12.17.21268009 

Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron